![](/-/media/icons/2019/pharma/biomedtracker-icon.png?rev=fc7926a0385c4901b67c1887d9aac276)
Merus acquires North American rights to Cornerstone's Factive and Spectracef
Executive Summary
In a move to exit the primary care market and focus on selling hospital-based drugs, Cornerstone Therapeutics Inc. (a specialty drug division owned 51% by Chiesi Farmaceutici SPA) has sold Merus Labs International Inc. North American rights to two antibiotics--Factive (gemifloxacin mesylate) 320mg tablets and Spectracef (cefditoren pivoxil). Specific financial terms were not disclosed but Merus paid total consideration up-front as a multiple of product cash flow.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice